




SUPPLEMENTARY FIGURES



Supplementary Figure 1. MiR-139-5p expression in ECFCs from healthy or diabetic subjects when treated with miR-139-5p mimics or inhibitors. MiR-139-5p expression was detected by real-time PCR in healthy adults derived-ECFCs transfected with miR-139-5p mimics (A) and in diabetic patients-derived ECFCs transfected with miR-139-5p inhibitors (B). (N=3) **P*<.05 versus control. Data shown in the graphs represent mean ± standard deviation.



Supplementary Figure 2. (A, B) Tube formation and migration of HUVECs transfected with miR-139-5p mimics or inhibitors. The photos were captured by a 40X microscope and statistics performed by Image J. (N=3) **P*<.05 versus control. (C) PDGF-B and VEGF expression in HUVECs transfected with miR-139-5p mimics or inhibitors. (N=3) **P*<.05 versus control. Data shown in the graphs represent mean ± standard deviation.



Supplementary Figure 3. C-jun, PDGF-B, and VEGF expression after transfection with c-jun siRNA or c-jun plasmid in diabetic ECFCs. PDGF-B and VEGF expression of normal ECFCs transfected with si-jun and DM ECFCs transfected with c-jun plasmid was detected by Western blot. (N=3) * $P < .05$ versus diabetic ECFCs. Data shown in the graphs represent mean \pm standard deviation.